Microsoft word - patent expiration table 010912nh.doc
Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
Estimated Dates of Possible First Time Generic/ Rx-to-OTC Market Entry 2010 US Retail Brand Name Generic name Common use(s) (in millions)^ Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
2010 US Retail Brand Name Generic name Common use(s) (in millions)^ Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
2010 US Retail Brand Name Generic name Common use(s) (in millions)^ Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
2010 US Retail Brand Name Generic name Common use(s) (in millions)^ Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
2010 US Retail Brand Name Generic name Common use(s) (in millions)^ Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
2010 US Retail Brand Name Generic name Common use(s) (in millions)^ Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
2010 US Retail Brand Name Generic name Common use(s) (in millions)^ Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
2010 US Retail Brand Name Generic name Common use(s) (in millions)^ Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
2010 US Retail Brand Name Generic name Common use(s) (in millions)^ Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
2010 US Retail Brand Name Generic name Common use(s) (in millions)^
^ Dollar amount reflects combined sales of all strengths and formulations of the product, unless otherwise indicated; source IMS Health 1 Lexapro’s '712 patent was originally slated to expire in December 2009, which included an additional six months of pediatric exclusivity. The U.S. Patent & Trademark Office granted the patent an 828-day extension in March 2006. Therefore, the estimated date for generic availability changed to March 2012. A recent patent litigation decision has also sided with Forest, upholding the validity of a key patent on Lexapro and keeping generics off the market until patent expiration in 2012. 2 Several companies have announced the settlement of patent litigation relating to Desloratadine Tablets, 5 mg (Clarinex). Pursuant to these settlements, the generic manufacturers will have the right to market Desloratadine Tablets, 5 mg, in the U.S. on July 1, 2012, or earlier in certain circumstances. Clarinex and Clarinex D will likely be switched to OTC availability prior to generic availability. 3 Generic Plavix was approved 1/20/06 with paragraph IV certification giving Apotex 180-day exclusivity. Apotex launched their generic “at risk” on August 8, 2006. A preliminary injunction was granted on August 31, ordering Apotex to halt its sales of generic Plavix. The judge did not require Apotex to recall clopidogrel that had already been distributed. Bristol-Myers Squibb/Sanofi’s patent infringement trial against Apotex began January 22, 2007. 4 Mylan launched their first-time generic for Xopenex inhalation solution 0.25% with 180 day exclusivity in September 2009. In April 2008, Breath Limited received FDA approval for their generic Xopenex inhalation solution 0.021%, .0042%, and 0.0103%. Sepracor settled a patent dispute with them which will allow Breath to market generic versions of the drug beginning August 2012 with a 180-day exclusive license. In March 2009, Sepracor entered into a Settlement and License Agreement with Teva and Barr. The agreement permits Barr and Teva to launch generic versions of Xopenex inhalation solution dosages under terms of a non-exclusive license commencing on February 17, 2013. 5 Diovan received pediatric exclusivity, extending the drug's patent protection in the US until September 2012. 6 Patent litigation is ongoing between Teva and Merck with regard to Temodar. The U.S. Court of Appeals for the Federal Circuit court is reviewing an appeal by Merck. If the Appeals court agrees that Merck’s patent for Temodar is unenforceable, Teva may launch their generic at any time. 7 Warner Chilcott sued Watson for patent infringement on Loestrin 24 FE in 2006. A settlement was reached in January 2009. Warner Chilcott sued Lupin for patent infringement on Loestrin 24 FE in September 2009. 8 In October 2007, Teva received FDA approval of its ANDA for Actonel 5 mg, 30 mg, and 35 mg tablets but did not launch due to ongoing patent litigation. In February 2008, the U.S. District Court for the District of Delaware found Procter & Gamble’s U.S. Patent No. 5,538,122 covering Actonel to be valid. Teva intends to appeal this decision.
Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities… 9 Boehringer Ingelheim sued Teva/Barr for patent infringement on Aggrenox in July 2007. The companies announced a settlement agreement in August 2008.
Note: Pulmicort dry powder inhalation and Advair have been removed from the table. These both contain inhaled corticosteroids, and the FDA has not determined a standard for bioequivalence for inhaled corticosteroids in multi-dose inhalers (MDIs) or dry powder inhalers (DPIs). Therefore, generic availability may be significantly delayed. At this time, there is no estimated date of generic approval.
Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved.
LACTOPHAR® Pro- en prebiotica I n g r e d i ë n t e n : Wetenschappelijke naam Nederlandse benaming Gebruikte deel Hoeveelheid V e r p a k k i n g : Doos van 10 & 30 tabletten A . D . H . : P r o d u c t b e s c h r i j v i n g : Weinig mensen lijken zich te realiseren dat de meeste bacteriën levensnoodzakelijk zijn. Zo ziet men dat het hebben van een ste
of gene-expression profiling to assess cancer prognosis and guide therapy;on the sidelines, we may very well find ourselves in the scientificthe use of genotyping to stratify patients according to the risk of a disease,“reruns” instead of at the forefront of novel, cutting-edge research. such as prolonged QT interval syndrome or myocardial infarction; the use Stephan Ziegeler, M.D., Byr